Vitreous Opacity Following Intravitreal Brolucizumab Injection: A Case Series Review
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To investigate cases of vitreous opacity (VO) similar to asteroid hyalosis (AH) after intravitreal brolucizumab injection. Methods: A retrospective chart review was conducted to identify cases showing VO similar to AH among patients who received intravitreal brolucizumab injections at our retinal clinic from January 2022 to January 2023. Results: A total of 220 brolucizumab injections were administered at our hospital. VO, showing yellow-white brilliant reflective particles, was found in six patients (2.7%). When VO occurred, all patients complained of floaters, although none of them complained of other symptoms including decreased visual acuity, pain, or conjunctival redness. The mean number of brolucizumab injections was 2.57 ± 2.38. No significant visual impairment was observed while VO was present. VO improved in all cases, and four cases improved without any treatment. The mean interval from onset to disappearance of VO was 8.0 ± 3.1 weeks. Conclusions: VO, similar to AH, can occur with a relatively high probability after intravitreal brolucizumab injections. Patients complained of severe floaters, but VO was not accompanied by other symptoms including vision impairment, injection, and pain. The VO disappeared after approximately 4 to 14 weeks. In case that other inflammatory findings are not severe, close follow-up without treatment may be sufficient. If a patient complains of floaters after an intravitreal brolucizumab injection, close fundus observation is necessary to evaluate the VO.
Abstract
Purpose: To investigate cases of vitreous opacity (VO) similar to asteroid hyalosis (AH) after intravitreal brolucizumab injection. Methods: A retrospective chart review was conducted to identify cases showing VO similar to AH among patients who received intravitreal brolucizumab injections at our retinal clinic from January 2022 to January 2023. Results: A total of 220 brolucizumab injections were administered at our hospital. VO, showing yellow-white brilliant reflective particles, was found in six patients (2.7%). When VO occurred, all patients complained of floaters, although none of them complained of other symptoms including decreased visual acuity, pain, or conjunctival redness. The mean number of brolucizumab injections was 2.57 ± 2.38. No significant visual impairment was observed while VO was present. VO improved in all cases, and four cases improved without any treatment. The mean interval from onset to disappearance of VO was 8.0 ± 3.1 weeks. Conclusions: VO, similar to AH, can occur with a relatively high probability after intravitreal brolucizumab injections. Patients complained of severe floaters, but VO was not accompanied by other symptoms including vision impairment, injection, and pain. The VO disappeared after approximately 4 to 14 weeks. In case that other inflammatory findings are not severe, close follow-up without treatment may be sufficient. If a patient complains of floaters after an intravitreal brolucizumab injection, close fundus observation is necessary to evaluate the VO.
참고문헌 (26)
- Ricci F, "Neovascular age-related macular degeneration : therapeutic management and new-upcoming approaches", Int J Mol Sci, 21, pp.8242~ (2020)
- Motevasseli T, "Side effects of brolucizumab", J Ophthalmic Vis Res, 16, pp.670~675 (2021)
- Gaudreault J, "Preclinical pharmacology and safety of ESBA1008, a single-chain antibody fragment, investigated as potential treatment for age related macular degeneration", Invest Ophthalmol Vis Sci, 53, pp.3025~ (2012)
- Sharma A, "Brolucizimab-leading an era of structural revolution for longterm VEGF suppression", Eye(Lond), 34, pp.611~613 (2020)
- Mohammadi SS, "Production of specific anti-EGFR single chain antibodies : a promising strategy in the immunotherapy of EGFR expressing tumor tissues", Iran J Cancer Prev, 10, pp.e6666~ (2017)
- "Novartis provides update on use and safety of Beovu in patients with wet AMD" (2020)[URL]
- Baumal CR, "Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab", Ophthalmology, 127, pp.1345~1359 (2020)
- Iyer PG, "Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment : a clinicopathologic case study", Am J Ophthalmol Case Rep, 20, pp.100989~ (2020)
- Dugel PU, "HAWK and HARRIER:phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration", Ophthalmology, 127, pp.72~84 (2020)
- Yoshikawa Y, "Vitreous noise on optical coherence tomography as an early finding of brolucizumab-related intraocular inflammation", Case Rep Ophthalmol, 12, pp.797~803 (2021)
- Jabs DA, "Standardization of uveitis nomenclature for reporting clinical data : results of the First International Workshop", Am J Ophthalmol, 140, pp.509~516 (2005)
- Williams PD, "Noninfectious vitritis after intravitreal injection of anti-VEGF agents : variations in rates and presentation by medication", Retina, 36, pp.909~913 (2016)
- Goldberg RA, "Noninfectious inflammation after intravitreal injection of aflibercept : clinical characteristics and visual outcomes", Am J Ophthalmol, 158, pp.733~737 (2014)
- Anderson WJ, "Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs : a narrative review", Int J Retina Vitreous, 7, pp.37~ (2021)
- Tadayoni R, "Brolucizumab : a newly developed anti-VEGF molecule for the treatment of neovascular age-related macular degeneration", Ophthalmologica, 244, pp.93~101 (2021)
- Kaya M, "Non-infectious intraocular inflammation following intravitreal anti-vascular endothelial growth factor injection", Turk J Ophthalmol, 51, pp.32~37 (2021)
- Pilli S, "Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting", Am J Ophthalmol, 145, pp.879~882 (2008)
- Khoshnevis M, "Asteroid hyalosis-a comprehensive review", Surv Ophthalmol, 64, pp.452~462 (2019)
- Castilla-Marti M, "Effect of vitreous opacities on straylight measurements", Retina, 35, pp.1240~1246 (2015)
- Fawzi AA, "Asteroid hyalosis in an autopsy population : the University of California at Los Angeles(UCLA)experience", Arch Ophthalmol, 123, pp.486~490 (2005)
- Bard LA, "Asteroid hyalitis : relationship to diabetes and hypercholesterolemia", Am J Ophthalmol, 58, pp.239~242 (1964)
- Jervey ED, "Asteroid hyalitis : a study of serum calcium levels in affected patients", South Med J, 58, pp.191~194 (1965)
- Smith JL, "Asteroid hyalitis : incidence of diabetes mellitus and hypercholesteremia", J Am Med Assoc, 168, pp.891~893 (1958)
- Potter JW, "Vision symptoms with asteroid bodies in the vitreous", J Am Optom Assoc, 55, pp.419~422 (1984)
- Verhoeff FH, "Microscopic findings in a case of asteroid hyalitis", Am J Ophthalmol, 4, pp.155~160 (1921)
- Hwang JC, "Optical coherence tomography in asteroid hyalosis", Retina, 26, pp.661~665 (2006)